Peter Glazer, M.D., Ph.D.
Cybrexa Chief Medical Advisor
Dr. Glazer is currently the Hunter Professor and Chairman of the Department of Therapeutic Radiology and Professor of Genetics at Yale. He leads a highly productive program in cancer research, with over 160 publications and with consistent NIH funding for over 25 years. A primary thrust of his lab has been elucidating the regulation of DNA repair in cancer and developing novel agents to exploit DNA repair for cancer therapy. He is credited with making the seminal observation that tumor hypoxia promotes genetic instability, and he has systematically dissected the mechanism for this effect, revealing that DNA repair is dysregulated in hypoxic cancer cells. Dr. Glazer has also pioneered the use of triplex-forming oligonucleotides for targeted gene editing, with recent work demonstrating successful gene editing in a living animal by simple intravenous administration of oligonucleotide-containing nanoparticles, providing a potentially safer and simpler alternative to CRISPR. Dr. Glazer received a BA in Chemistry from Harvard in 1979, an MS in Biochemistry from the University of Oxford in 1981, and an MD and PhD (in Genetics) from Yale in 1987. He has served as Chairperson of the Radiation Therapeutics and Biology Study Section for NIH, as well as on councils and program committees for several national societies. He has also led the Yale Cancer Center’s Radiobiology & Radiotherapy research program for more than 15 years. Dr. Glazer has received awards from the Radiation Research Society, the American Society for Photobiology, and the Leukemia and Lymphoma Society, and was elected to the Association of American Physicians in 2014.
5 Science Park 395 Winchester Ave. New Haven, CT 06511 (860) 717-2731